Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 17/20 | 0.55 |
| ▸ | KDR | P35968 | 15/20 | 0.55 |
| ▸ | EPHB4 | P54760 | 13/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.55 |
| ▸ | FLT1 | P17948 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794957 | 0.94 | EGFR (0.57) | EGFREPHA2KDREPHB4ERBB2 | |
| SCHEMBL6794421 | 0.92 | EGFR (0.63) | EGFREPHA2KDREPHB4ERBB2 | |
| SCHEMBL6800284 | 0.92 | EGFR (0.55) | EGFREPHA2KDREPHB4ERBB2 | |
| SCHEMBL6792872 | 0.88 | EGFR (0.76) | EGFREPHA2KDR | |
| SCHEMBL6793039 | 0.87 | EGFR (0.61) | EGFREPHA2KDRERBB2FLT1 | |
| SCHEMBL6794980 | 0.86 | EGFR (0.59) | EGFRKDR | |
| SCHEMBL6793769 | 0.85 | EGFR (0.52) | EGFREPHA2KDREPHB4 | |
| SCHEMBL30640294 | 0.84 | EGFR (0.66) | EGFREPHA2KDREPHB4ERBB2 | |
| SCHEMBL6794779 | 0.84 | EGFR (0.76) | EGFRKDRERBB2 | |
| SCHEMBL6793151 | 0.84 | EGFR (0.59) | EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835735-B2 | Anticancer, tyrosine kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-12-28 | — | — | US | disclosed |
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | KOREAN INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | EGFR, ERBB2, ERBB4 | EGFR 1/4885EPHA2 228/4885KDR 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.